NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Skye is a clinical stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Alleg.

WW International (WW) delivered a strong Q3, exceeding revenue and EBITDA expectations, driven by its Clinical Business. WW faces ongoing challenges, including declining Behavioral subscribers and cautious Q4 guidance, which may keep investors wary until trends improve. Key catalysts ahead include FDA decisions on GLP-1 compounding, expanded insurance coverage, and new partnerships with pharma and insurance providers.

TQQQ is the cleanest, most liquid 3x Nasdaq-100 ETF, with tight spreads and a reasonable 0.82% yearly fee. TQQQ has outperformed QQQ and peers over the past 15 years, driven by a secular tech bull market and recently AI. This made me rethink my approach to leveraged investing. For short-term AI rebound trades, I still favor SOXL over TQQQ; semiconductors capture the most upside if an AI hype cycle is to reignite. Long term, I am considering TQQQ.

CLS' new SD6300 storage system targets soaring AI data needs with an ultra-dense design aimed at boosting performance and cost efficiency.

Does TIM S.A. Sponsored ADR (TIMB) have what it takes to be a top stock pick for momentum investors?

Oric Pharmaceuticals (ORIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TriMas (TRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

First Bank (FRBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Ares Commercial Real Estate (ACRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Jade Biosciences, Inc. (JBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Virgin Galactic (SPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PLBY Group (PLBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Developers desperately need access to electricity—and bitcoin miners are in a prime position to assist.

WALLDORF, Germany , Nov. 18, 2025 /PRNewswire/ -- SAP SE (NYSE: SAP) today announced a new collaboration with France's AI sector, which includes new and expanded partnerships with Bleu, Capgemini, and Mistral AI. The collaboration will combine SAP enterprise application expertise with France's vibrant AI ecosystem to create secure, scalable, AI-driven sovereign cloud solutions that protect data and intellectual property while advancing Europe's digital transformation.

During 2025, PG&E customers have lost nearly $300,000 to scammers OAKLAND, Calif. , Nov. 18, 2025 /PRNewswire/ -- As the holiday season gets underway, Pacific Gas and Electric Company (PG&E) is joining Utilities United Against Scams to help customers recognize potential scams and to "slow down, verify and stop the scam" as part of Utility Scam Awareness Day on November 19.

DALLAS , Nov. 18, 2025 /PRNewswire/ -- The Board of Directors of Jacobs (NYSE:J) has declared a quarterly cash dividend payable to shareholders in the amount of $0.32 per share of Jacobs common stock. This dividend will be paid on Dec. 19, 2025, to shareholders of record as of the close of business on Dec. 2, 2025.

Shares of Microsoft and Amazon came under renewed pressure on Tuesday as a rare analyst downgrade and fresh regulatory scrutiny from the European Union weighed on two of Wall Street's most influential technology stocks.

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.